{"preliminary_commentary":{"by_channel":{"x_thread":5,"youtube":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02445391\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"EA1131","nct_id":"NCT02445391","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ea1131-nct02445391. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients undergo observation.","label":"Arm A (observation) (closed to accrual 05/16/2016)","type":"NO_INTERVENTION"},{"description":"Patients receive cisplatin IV or carboplatin IV on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.","label":"Arm B (cisplatin or carboplatin)","type":"EXPERIMENTAL"},{"description":"Patients receive capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.","label":"Arm C (capecitabine)","type":"ACTIVE_COMPARATOR"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2031-03-29","type":"ESTIMATED"},"conditions":["Estrogen Receptor Negative","HER2/Neu Negative","Invasive Breast Carcinoma","Progesterone Receptor Negative","Stage II Breast Cancer","Stage IIA Breast Cancer","Stage IIB Breast Cancer","Stage III Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer","Triple-Negative Breast Carcinoma"],"enrollment":{"count":415,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Capecitabine","otherNames":["Xeloda"],"type":"DRUG"},{"name":"Carboplatin","otherNames":["Paraplatin","Carboplatin Novaplus"],"type":"DRUG"},{"name":"Cisplatin","otherNames":["Platinol-AQ","Platinol"],"type":"DRUG"}],"last_update":"2026-10-02","lead_sponsor":"ECOG-ACRIN Cancer Research Group","official_title":"A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2021-04-07","type":"ACTUAL"},"primary_outcomes":[{"measure":"3-year Invasive Disease-Free Survival (IDFS) Rate in Basal-Subtype Patients","timeFrame":"No mandatory timeline, assessed at any time as a standard of care procedure or at the investigator's discretion; data reported every 3 months within 2 years from randomization, every 6 months if 2-3 years."}],"references":[{"citation":"Smith KL, Zhao F, Mayer IA, Tevaarwerk AJ, Garcia SF, Arteaga CL, Symmans WF, Park BH, Burnette BL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Brown-Glaberman U, Flaum LE, Mayer EL, Sikov WM, Rodler ET, DeMichele AM, Sparano JA, Wolff AC, Miller KD, Wagner LI. Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131. Cancer. 2024 May 15;130(10):1747-1757. doi: 10.1002/cncr.35187. Epub 2024 Jan 18.","pmid":"38236702","type":"DERIVED"},{"citation":"Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. J Clin Oncol. 2021 Aug 10;39(23):2539-2551. doi: 10.1200/JCO.21.00976. Epub 2021 Jun 6.","pmid":"34092112","type":"DERIVED"}],"start_date":{"date":"2015-10-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy","url":"https://clinicaltrials.gov/study/NCT02445391"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ea1131-nct02445391"}